Core Viewpoint - He Eye Hospital has decided to terminate the cross-border e-commerce project of Hainan He Eye Color Trading Co., Ltd. due to unsatisfactory performance and market conditions, aiming to enhance the efficiency of fund utilization and protect shareholder interests [1] Group 1 - The project had a total budgeted investment of 26 million yuan [1] - The decision was made during the third board and supervisory board meetings held on April 23, 2025 [1] - Remaining raised funds will be transferred to a special account for excess raised funds and the corresponding special account will be canceled [1]

Core Viewpoint - Guangzheng Eye Hospital Group Co., Ltd. reported a significant decline in revenue and net profit for 2024, indicating ongoing challenges in its business transformation efforts [2][4]. Financial Performance - The company achieved a revenue of 893 million yuan, a year-on-year decrease of 16.94% [2]. - The net profit attributable to shareholders turned from profit to a loss of 175 million yuan, a drastic decline of 1987.12% year-on-year [2]. - The non-recurring net profit has remained negative for 12 consecutive years [2]. Business Segment Analysis - The medical sector generated 778 million yuan in revenue, down 6.88% year-on-year, accounting for 87.17% of total revenue [3]. - The steel structure segment saw a revenue drop of 61.78% to 79.19 million yuan, representing 8.87% of total revenue [3]. - The energy sector reported a revenue increase of 10.66% to 35.36 million yuan, making up 3.96% of total revenue [3]. Major Projects and Challenges - The refractive and cataract projects in the eye care business generated revenues of 258 million yuan and 288 million yuan, respectively, both showing declines of 13.09% and 8.88% year-on-year [3]. - The company has opened 14 specialized eye hospitals and 3 vision clinics in 10 major cities [3]. - The company has cumulatively recognized goodwill impairment provisions of 374 million yuan, with 135 million yuan recognized in 2024 alone for two acquired eye hospitals [4]. Strategic Transformation - Guangzheng Eye Hospital has undergone several strategic shifts, moving from steel structure operations to focusing on eye care services [5][6]. - The company had high expectations for its eye care business, but it has not yet yielded the anticipated results, leading to further losses [4][7]. - The competitive landscape in the eye care industry has intensified, impacting the company's revenue and profit margins [4][7].

Core Viewpoint - Guangzheng Eye Hospital reported a revenue of 893 million yuan for 2024, with a net profit attributable to shareholders of -175 million yuan, while cash flow from operating activities increased by 77.54% to 69.07 million yuan [1] Group 1: Financial Performance - The company experienced a decline in revenue due to weak domestic consumption and intensified industry competition, particularly in the ophthalmology sector [2] - The steel structure segment faced significant revenue decline due to external industry pressures, while the energy board maintained stable rental income [2] - Core businesses in refractive and cataract surgery generated revenues of 258 million yuan and 288 million yuan, respectively, accounting for 61.15% of total revenue, with gross margins of 43.86% and 49.87% [3] Group 2: Strategic Initiatives - The company is focusing on high-end cataract surgeries and refractive procedures to meet the increasing quality demands of patients, transitioning from basic cataract surgeries to advanced refractive cataract surgeries [3] - Guangzheng Eye Hospital is enhancing its academic and research capabilities through partnerships with Fudan University and Jiangnan University, contributing to innovative breakthroughs in corneal cross-linking treatments and other research projects [4] - The company is committed to social responsibility through its "technology + public welfare" approach, conducting vision restoration surgeries in high-altitude regions [4] Group 3: Future Development Plans - Over the next three years, the company aims to deepen its focus on ophthalmology, enhance smart hospital construction, and integrate AI into its services, management, and operations [5] - The strategic direction includes a focus on cataract as a foundation, refractive vision as a center, and breakthroughs in ocular surface and cosmetic surgery [5] - The company plans to leverage technological upgrades and digital innovations to overcome profitability challenges and achieve high-quality growth in a competitive landscape [5]

前十大流通股东累计持有： 15167.12万股，累计占流通股比： 29.85%，较上期变化： -991.29万股。 | 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 光正投资有限公司 | 12916.87 | 25.41 | 不变 | | KING JOIN GROUP LIMITED | 508.52 | 1.00 | 不变 | | 乌鲁木齐绿保能教育咨询有限公司 | 313.89 | 0.62 | 不变 | | 寻艳红 | 300.00 | 0.59 | -651.56 | | 贾君华 | 268.00 | 0.53 | 37.00 | | 宋益群 | 232.33 | 0.46 | 不变 | | 刘静芳 | 160.75 | 0.32 | 新进 | | 李明 | 159.88 | 0.31 | 新进 | | 邱琬书 | 155.22 | 0.31 | 新进 | | 罗文华 | 151.66 | 0.30 | -123.00 | | 较上个报告期退出前十大股东有 | | | | | 陈立云 | 266.40 | 0.5 ...

光正眼科（002524）公告，2024年营业收入8.93亿元，同比下降16.94%。归属于上市公司股东的净亏损 1.75亿元，去年同期净利润925.5万元。基本每股收益-0.34元/股。公司计划不派发现金红利，不送红 股，不以公积金转增股本。 ...

近日，在第九届爱尔眼科（300015）泰山高峰论坛会议上，泰安光明爱尔眼科医院微创全飞秒精准4.0系统正式揭牌！这标 志着泰安屈光手术迈入"更精准、更智能"的4.0时代。 什么是微创全飞秒精准4.0？ 据了解，泰安光明爱尔眼科医院自2018年率先引进全飞秒3.0技术以来，已累计完成数千例全飞秒手术，为泰安近视患者带 来清晰视界。此次学术会议，医院再次引领技术革新，正式发布全飞秒精准4.0-VISULYZE技术！想知道什么是微创全飞秒 精准4.0，那要先了解一下微创全飞秒3.0。 泰安光明爱尔眼科医院屈光手术专科朱涛主任介绍，微创全飞秒3.0是利用飞秒激光制作角膜基质透镜，再通过2-4mm微切 口取出，从而达到矫正近视的目的。具有无瓣、微创、对角膜组织损伤更小，角膜生物力学稳定性更好、患者术中体验更 舒适等多个优势。 据了解，微创全飞秒精准4.0-VISULYZE是新一代的微创全飞秒精准手术解决方案，是在标准全飞秒SMILE3.0的基础上引入 个性化Nomogram科学分析软件(VISULYZE)，大数据统计量化分析手术安全性、稳定性、有效性、可预测性，使临床效果 可视化，全环境、全流程、全变量控制影响因素，个 ...

以下文章来源于雷达Finance ，作者X编辑 雷达Finance . 遨游广袤的财富世界。 来源|雷达财经 文 |孟帅 编|深海 身为眼科医疗界风云人物的苏庆灿，遭遇财富大缩水。 2023年，苏庆灿以255亿元身家强势闯入《胡润全球富豪榜》，成为莆田商帮的耀眼新星。但在今年最新出炉的榜单中，苏庆灿的财富仅剩90亿 元。短短两年过去，其身家足足少了165亿元。 回溯过去，这位从莆田走出的眼科大佬，早年毅然抛下"铁饭碗"投身商海。凭借敏锐的商业嗅觉，在贸易领域积攒下原始资本的苏庆灿，在千禧年后 精准捕捉到眼科医疗的蓝海机遇，豪掷3500万元拿下厦门眼科中心。 在他的带领下，华厦眼科一路开疆拓土，逐渐成为眼科医疗赛道的头部玩家之一。然而，如今苏庆灿财富暴跌的背后，折射出华厦眼科业绩承压的严 峻现实。 尽管华厦眼科标榜多项指标位居行业前列，但其业绩较为依赖华东地区。去年前三季度，华厦眼科营收仅微增2.55%，净利润同比更是缩水近1/4。 与龙头爱尔眼科相比，其营收、净利润的规模差距悬殊。 更添变数的是，2023年12月，苏庆灿突遭上海市监察委员会留置。后续留置措施虽于2024年6月解除，但据彼时公司披露的公告显示， ...

Group 1 - Shenzhen Aier Eye Hospital was fined 717.5 yuan for illegal medical advertising by the Shenzhen Market Supervision Administration [1][2] - The penalty was based on the Advertising Law of the People's Republic of China, which stipulates fines for various advertising violations [2] - The penalty decision was made on April 18, 2025, and the hospital is a subsidiary of Aier Eye Hospital Group, holding a 91% stake [3] Group 2 - In 2023, Shenzhen Aier Eye Hospital reported an operating income of 296 million yuan and a net profit of 58.5 million yuan [3] - The hospital primarily engages in ophthalmology medical services and optical dispensing [3] - The registered capital of Shenzhen Aier Eye Hospital is 45 million yuan [4]

2025年4月17日，由 眼未来｜思宇MedTech主办 ，中关村联新生物医药产业联盟、北京中关村科学城创新发展有限公司、北京中关村创业大街科技服务有限公司、 启迪之星、中关村科学城CGT产业孵化中心协办的 首届全球眼科大会（Global Ophthalmology Conference 2025） 在北京市中关村自主创新示范区展示交易中心隆 重召开。 本次大会汇聚来自 医疗器械、临床医学、人工智能、生命科学、投资与政策 等多个领域的顶尖专家与核心企业代表，现场参会人数 超过600人 ，盛况空前。 大会 通过 "政策+技术+转化+资本" 的跨界融合视角，聚焦眼科产业链全景发展，呈现出一场高度专业、极具前瞻性的行业盛会。 大会开幕式由思宇MedTech医疗科技媒体创始人、中关村联新生物医药产业联盟秘书长 赵清 主持。 海淀区副区长 林航 在开场致辞中指出，眼健康是国家健康战略的重要组成部分，海淀区将持续以"数据+场景+空间+机制"四位一体的方式，推动眼科医疗器械、人 工智能、生物材料等方向的科技成果在本地率先落地转化。她表示，海淀愿做创新医疗生态的首站平台，为临床专家、科研人员和企业家提供更优质的成长土壤。 北 ...

何氏眼科回复：尊敬的投资者您好，公司注意到近期股价处于低位。股价的波动受多种因素综合影响， 包括宏观经济环境、行业动态、市场情绪等。公司一直高度重视市值管理工作，并采取了一系列措施来 提升公司价值和股东回报：1.聚焦公司战略，稳健经营：公司紧紧围绕发展战略，立足主营业务，深耕 眼科市场，不断深化科技创新，加大消费医疗属性业务占比，积极降本增效。同时密切关注眼科领域的 前沿技术，夯实医疗数字化建设，推动眼科医疗服务向智能化、个性化的方向发展。在业务模式创新 上，探索并推动轻资产业务模式，保持合理的业务的扩张。2.公司以医、教、研三大平台协同发展为基 础，将科技创新作为引擎，围绕视网膜干细胞、视网膜干细胞与肿瘤、眼遗传病学等方面进行深入研 究。3.公司会通过设立的产业基金加快眼科医疗技术创新、眼科器械、眼科药物等眼健康全产业链布 局。4. 践行积极稳健可持续的投资者回报：公司一贯重视股东回报，上市以来，公司已连续三年实施完 成现金分红，累计现金分红约3.25亿元（含税），持续提升投资者回报。5.加强投资者关系管理：通过 多种方式与投资者交流沟通，确保公司内在价值得到充分的传递和展现，多措并举推动市场价值与内在 价 ...